ArticleArchives of Razi Institute2024
Design, Synthesis and
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The H5N1 subtype of the influenza virus is highly pathogenic and lethal to humans and animal. The necessity for the development of new vaccines with a broad spectrum of efficacy against this pathogen seems to be very crucial. One highly regarded solution to this problem is to design and production of recombinant vaccines using the conserved peptide of influenza viruses. A search of international databases yielded the peptide sequence of the M2e fragment of H5N1 viruses isolated from Iran, as well as a variety of conserved peptide sequences of fragments of HA1, HA2, NA and NP of other H5N1 viruses. These sequences were obtained for both MHC receptors in mice. Subsequently, these fragments, in conjunction with a PADRE sequence, were connected by bioinformatics to design a fusion epitopic construct. Subsequently, the construct was optimized for expression in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.